vimarsana.com

Page 160 - அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

How to Choose Birth Control When You Have Migraine

Everyday Health Identifying the best birth control option while managing migraine is a complex yet surprisingly common health issue. According to the American Migraine Foundation, about one in five women in the United States has migraine, and the disease is most prevalent for women in their twenties, thirties, and forties. In other words, it occurs at the time in life when many women choose to use some form of contraception. Finding the right form of birth control can take some trial and error. It’s definitely not one-size-fits-all, says Julie M. Levitt, MD, an obstetrician-gynecologist at The Women’s Group of Northwestern in Northbrook, Illinois.

ACC, AHA Issue Updated Performance Measures for Adults with Atrial Fibrillation or Atrial Flutter

ACC, AHA Issue Updated Performance Measures for Adults with Atrial Fibrillation or Atrial Flutter ECG with paroxysm correct form of atrial flutter. Getty Images December 23, 2020  The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two updates to its Clinical Performance and Quality Measures on Atrial Fibrillation or Atrial Flutter. The writing committee for this 2020 document incorporated two changes to performance measures in accordance with the 2019 ACC/AHA/Heart Rhythm Society atrial fibrillation guideline focused update.  Atrial fibrillation (AF or Afib) increases the risk of ischemic stroke five fold, and in the setting of mitral stenosis it drives up the risk of stroke twenty fold over that of patients with a normal heartbeat. Atrial flutter also significantly raises the chance of stroke, and the likelihood increases with certain risk factors. 

New US Valve Guidance Tackles TAVR vs TAVI, Low-risk AS, Functional MR

December 23, 2020 Guidelines for the management of valvular heart disease (VHD) have been refreshed by the American College of Cardiology and American Heart Association the first full revision since 2014. Most salient among the changes is the inclusion of the pivotal low-risk TAVR trials that led to US Food and Drug Administration approval for that indication last fall. With Catherine M. Otto, MD (University of Washington, Seattle), and Rick A. Nishimura, MD (Mayo Clinic, Rochester, MN), as co-chairs, the multisociety-produced document was published online last week in both Circulation and the Journal of the American College of Cardiology. Patrick T. O’Gara, MD (Brigham and Women’s Hospital, Boston, MA), one of its authors, told TCTMD that, as for any guideline recommendations, what motivated the revision was the “publication of practice-changing science.” Beyond the low-risk TAVR trials, other influential studies included here are COAPT and MITRA-FR, both in the mitra

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.